Breaking News Instant updates and real-time market news.

INCY

Incyte

$77.43

-0.34 (-0.44%)

10:55
10/21/19
10/21
10:55
10/21/19
10:55

JMP Securities biotech analyst to hold an analyst/industry conference call

Biotechnology Benjamin, along with Key Opinion Leader Dr. David Rosmarin, key participating physician in the Incyte-sponsored Phase 2 and Phase 3 TRuE-V1 and TRuE-V2 trials for treatment of Vitiligo on an Analyst/Industry conference call to be held on October 21 at 11:30 am.

  • 21

    Oct

  • 29

    Oct

  • 06

    Nov

  • 07

    Dec

INCY Incyte
$77.43

-0.34 (-0.44%)

10/04/19
GUGG
10/04/19
NO CHANGE
GUGG
Guggenheim positively biased on Biotech heading into earnings
Guggenheim analysts Whitney Ijem, Etzer Darout, Yatin Suneja and Michael Schmidt offered a preview for their joint Biotech coverage ahead of the group's earnings reporting season. Biotech stocks continued their downward trend in the quarter amid negative market sentiment and the analysts think the bar for companies to raise 2019 guidance again may be a bit higher following increases in FY19 consensus estimates on the heels of strong Q2 earnings results. However, they are postively biased on the group and have confidence in FY19 guidance and estimates, the analysts said. They see Alexion (ALXN), Biogen (BIIB), Genmab (GMAB), GW Pharmaceuticals (GWPH), Incyte (INCY), Neurocrine (NBIX), Regeneron (REGN) and Seattle Genetics (SGEN) as well positioned relative to expectations, Ijem, Darout, Suneja and Schmidt tell investors.
10/14/19
PIPR
10/14/19
NO CHANGE
Target $95
PIPR
Overweight
Incyte data enchances confidence in $500M opportunity, says Piper Jaffray
Incyte over the weekend reported 52-week follow-up data for the Phase II topical ruxolitinib study in vitiligo patients. Previously, Incyte reported positive 24-week data, which included significant improvements in F-VASI75 scores, with deeper responses for a considerable proportion of patients, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. This weekend's update demonstrated that topical ruxolitinib continues to be well tolerated and that patients achieved sustained and/or deeper responses at 52 weeks as the number of patients achieving F-VASI75 increased to 52% from 30% at 24 weeks, says the analyst. The data enhance his confidence that topical ruxolitinib is providing "meaningful and durable" clinical benefit to patients that otherwise do not have treatment options. He believes vitiligo could conservatively represent a $500M-plus sales opportunity. Van Buren keeps an Overweight rating on Incyte with a $95 price target.
10/16/19
PIPR
10/16/19
NO CHANGE
Target $95
PIPR
Overweight
Incyte REACH2 'a nice win,' data should be presented at ASH, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren notes that Incyte announced that REACH2, which is evaluating Jakafi in steroid-refractory acute GvHD, "nicely" met its primary response rate-based endpoint and he believes the data could be presented at ASH. Further, the company disclosed that the REACH3 trial is continuing as planned after an interim efficacy and safety review by the data monitoring committee, although the analyst estimates the data is now delayed until Q3 of 2020. Therefore, by year-end, the remaining major GvHD catalyst is the GRAVITAS-301 trial, which will likely come in December, Van Buren points out, adding that he believes should be a success. While the delay is "slightly frustrating," the analyst still finds the broader REACH2+3 update to be "encouraging" for the overall GvHD franchise, which could generate $500M-plus in sales by 2025. He has an Overweight rating and $95 price target.
10/16/19
STFL
10/16/19
NO CHANGE
STFL
Hold
Incyte REACH2 wins on ORR, secondary endpoint data just as important,says Stifel
Stifel analyst Stephen Willey believes Incyte's disclosure of top-line Phase 3 REACH2 results demonstrating ruxolitinib yields a statistically significant improvement in Day 28 overall response rate versus best available therapy in patients with steroid-refractory, acute graft-versushost-disease - the trial's primary efficacy endpoint - is in-line with most investor expectations. The analyst believes the yet-to-be-disclosed secondary efficacy endpoints will be of particular interest to both investors/clinicians. He also argues that the Phase 3 REACH3 trial evaluating ruxolitinib versus BAT in steroid-refractory chronic GVHD represents the more meaningful trial for his longer-term ruxolitinib estimates, but also likely carries the greatest risk. He has a Hold rating on Incyte's shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.